| Title: | Validity of European-centric cardiometabolic polygenic scores in multi-ancestry populations |
| Journal: | European Journal of Human Genetics |
| Published: | 5 Jan 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38182743/ |
| DOI: | https://doi.org/10.1038/s41431-023-01517-3 |
| URL: | https://www.nature.com/articles/s41431-023-01517-3.pdf |
| Citations: | 3 (3 in last 2 years) as of 8 Aug 2024 |
Publication 8993
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Polygenic scores (PGSs) provide an individual level estimate of genetic risk for any given disease. Since most PGSs have been derived from genome wide association studies (GWASs) conducted in populations of White European ancestry, their validity in other ancestry groups remains unconfirmed. This is especially relevant for cardiometabolic diseases which are known to disproportionately affect people of non-European ancestry. Thus, we aimed to evaluate the performance of PGSs for glycaemic traits (glycated haemoglobin, and type 1 and type 2 diabetes mellitus), cardiometabolic risk factors (body mass index, hypertension, high- and low-density lipoproteins, and total cholesterol and triglycerides) and cardiovascular diseases (including stroke and coronary artery disease) in people of White European, South Asian, and African Caribbean ethnicity in the UK Biobank. Whilst PGSs incorporated some GWAS data from multi-ethnic populations, the vast majority originated from White Europeans. For most outcomes, PGSs derived mostly from European populations had an overall better performance in White Europeans compared to South Asians and African Caribbeans. Thus, multi-ancestry GWAS data are needed to derive ancestry stratified PGSs to tackle health inequalities.</p>
4 Authors
- Constantin-Cristian Topriceanu
- Nish Chaturvedi
- Rohini Mathur
- Victoria Garfield
1 Application
| Application ID | Title |
|---|---|
| 7661 | Chronic disease outcomes across the glycaemic spectrum: harnessing UK Biobank and linked eHealth data to quantify risks, explore mechanisms and determine treatment impacts. |
Enabling scientific discoveries that improve human health